Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
M&A Deal

Abeona Therapeutics Acquires Phase 3 ABO-801 Asset in $20 Million All-Equity Deal

Abeona Therapeutics has acquired ABO-801, a Phase 3-ready candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals in a $20 million all-stock transaction. The acquisition expands Abeona's clinical pipeline with a differentiated oral therapy and includes a framework for an additional $60 million in contingent milestone payments.

Face mask, covid-19, epidemic, wuhan''s virus. Stock photo illustrating Abeona Therapeutics' M&A deal story.
ABEONA THERAPEUTICS INC. · Healthcare · Photo: leo2014 / Pixabay
Key numbers
Deal value$20M
Share of market cap8.4%
Share of annual revenue343.6%

Key highlights

  • Acquisition of APT-1011 (now ABO-801) for $20 million in upfront equity consideration
  • Deal structured with no upfront cash, issuing 4,494,383 common shares to the seller
  • Eligible for $30 million upon FDA approval and $30 million in sales milestones
  • ABO-801 is a once-daily oral disintegrating tablet with FDA Orphan Drug designation
  • Planned initiation of a new Phase 3 clinical study in the second quarter of 2027

Deal Structure & Terms

Abeona Therapeutics issued 4,494,383 shares of common stock to Ellodi Pharmaceuticals to satisfy the twenty million dollar upfront consideration, avoiding any immediate cash outlay. The transaction includes substantial contingent liabilities, with Ellodi eligible to receive thirty million dollars upon the successful FDA approval of a New Drug Application and an additional thirty million dollars upon reaching specific sales targets. Tiered royalties ranging from the low to mid-teens will also be paid on net sales. The upfront shares are subject to a staggered lock-up agreement, with one-third of the equity released at six, twelve, and eighteen-month intervals following the closing date.

Strategic Rationale

  • Targets eosinophilic esophagitis, a chronic inflammatory disease affecting approximately 360,000 diagnosed patients in the U.S.
  • Adds a candidate with existing FDA Orphan Drug and Fast Track designations to the pipeline
  • Utilizes a specialized oral disintegrating tablet formulation to provide topical esophageal delivery with low systemic exposure
  • Leverages data from two previous Phase 3 trials involving 361 patients to optimize future study design
  • Transitions the company toward a diversified commercial-stage profile with multiple value inflection points

Clinical Timeline & Roadmap

ABO-801 has undergone extensive clinical evaluation, including a Phase 2b dose-ranging study and two completed Phase 3 trials. While the previous late-stage studies did not meet their primary symptom-related endpoints, they achieved statistically significant results in endoscopic and histologic measures. Abeona plans to utilize these insights to launch a newly designed Phase 3 study in the second quarter of 2027. Under the current development timeline, the company expects to report topline results from this pivotal trial by the end of 2028, supported by ongoing data from an Expanded Access Program that has served over 260 participants.

Management Perspective

“The acquisition of ABO-801 is an important step in building Abeona into a diversified commercial-stage company with multiple opportunities for value inflection, adding an asset with substantial revenue potential in a rapidly growing disease.”

Vish Seshadri, Ph.D., CEO, Abeona Therapeutics

Financial & Market Context

  • Concurrently announced a $30 million private placement financing with leading life sciences investors
  • Recent $155 million sale of a Priority Review Voucher in May 2025 significantly strengthened the balance sheet
  • Management previously guided for at least 12 months of cash runway as of August 2026
  • Targeting a ramp-up in commercial manufacturing capacity to 10 runs per month by year-end 2026
ABEONA THERAPEUTICS INC. share price · last month
Line chart of ABEONA THERAPEUTICS INC.'s share price over the last month, from $4.41 on 19 Oct → $2.60 on 16 Nov; our story on 9 Nov at $4.17.

Down 37.6% since our story on 9 Nov: $4.17 when we broke it → $2.60 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$4.41
20 Oct$4.60
21 Oct$4.51
22 Oct$4.47
23 Oct$4.40
26 Oct$4.31
27 Oct$4.45
28 Oct$4.55
29 Oct$4.56
30 Oct$4.35
2 Nov$4.25
3 Nov$4.25
4 Nov$4.22
5 Nov$3.91
6 Nov$4.17
9 Nov$2.54
10 Nov$2.46
11 Nov$2.30
12 Nov$2.29
13 Nov$2.42
16 Nov$2.60
Earlier announcements by ABEONA THERAPEUTICS INC.
DateAnnouncementAmount
12 May 2025Sale of Rare Pediatric Disease Priority Review Voucher (PRV)Source: SEC filing$155.0 Million

Management commentary

“The acquisition of ABO-801 is an important step in building Abeona into a diversified commercial-stage company with multiple opportunities for value inflection, adding an asset with substantial revenue potential in a rapidly growing disease.”

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics

“We have strong conviction in the team and the opportunity and believe ABO-801 has the potential to offer a differentiated profile in EoE, supported by once-daily dosing and low systemic exposure.”

Lucian Iancovici, M.D., Partner, TPG
ABEONA THERAPEUTICS INC. · financial snapshot
Share price$4.17
Market cap$238M
Revenue (annual)$6M
1-month price change-17.91%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Abeona Therapeutics Inc. announcing the acquisition of assets from Ellodi Pharmaceuticals.

Read the filing ↗

Track ABEONA THERAPEUTICS INC. live

Get the next ABEONA THERAPEUTICS INC. SEC filing seconds after it lands.

More in M&A & Deals

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.